Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Pars plana vitrectomy and retinal detachment repair. Main billing specialty: ophthalmology.
Medicare fee-for-service vitreoretinal surgery cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 2 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 2 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| A R C Laser | 1 |
| Visioncare Devices | 1 |
Product codes: HQE (instrument, vitreous aspiration and cutting, ac-powered). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 30% of the cases CMS names in California; 51 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Cataract & MIGS | 8,406 | 1,858,437−1.3%/yr | −1.3%/yr | 2,081,700 in 2030+1.9%/yr |
Every procedure · Markets by state · Device companies · Compare two states
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 94 | 7,488−1.9%/yr | −1.9%/yr | 2.30.9× | 59% | 8,080 in 2030+1.3%/yr |
| Texas | 83 | 6,824−3.6%/yr | −3.6%/yr | 3.21.3× | 80% | 7,210 in 2030+0.9%/yr |
| Florida | 76 | 6,413−2.9%/yr | −2.9%/yr | 2.91.2× | 87% | 6,520 in 2030+0.3%/yr |
| New York | 42 | 3,504−3.3%/yr | −3.3%/yr | 1.90.8× | 48% | 3,660 in 2030+0.7%/yr |
| Ohio | 51 | 3,204−1.9%/yr | −1.9%/yr | 2.91.2× | 78% | 3,460 in 2030+1.3%/yr |
| Pennsylvania | 45 | 3,182−0.1%/yr | −0.1%/yr | 2.41.0× | 49% | 3,020 in 2030−0.9%/yr |
| Arizona | 32 | 2,892−3.5%/yr | −3.5%/yr | 3.91.6× | 99% | 3,110 in 2030+1.2%/yr |
| Illinois | 31 | 2,737−5.7%/yr | −5.7%/yr | 2.00.8× | 42% | 2,740 in 20300%/yr |
| Tennessee | 36 | 2,272−2.5%/yr | −2.5%/yr | 3.31.3× | 77% | 2,320 in 2030+0.3%/yr |
| North Carolina | 33 | 2,261−4%/yr | −4%/yr | 2.30.9× | 36% | 2,170 in 2030−0.7%/yr |
| Maryland | 30 | 2,121−7.2%/yr | −7.2%/yr | 2.41.0× | 26% | 2,290 in 2030+1.3%/yr |
| Virginia | 28 | 1,985−3.8%/yr | −3.8%/yr | 1.90.8× | 77% | 2,080 in 2030+0.8%/yr |
| Washington | 30 | 1,954−4.2%/yr | −4.2%/yr | 2.61.0× | 60% | 1,820 in 2030−1.2%/yr |
| Colorado | 31 | 1,941+1%/yr | +1%/yr | 4.01.6× | 75% | 2,470 in 2030+4.1%/yr |
| Missouri | 35 | 1,908−0.3%/yr | −0.3%/yr | 3.11.3× | 51% | 1,740 in 2030−1.5%/yr |
| New Jersey | 23 | 1,908−1.3%/yr | −1.3%/yr | 1.80.7× | 56% | 1,990 in 2030+0.7%/yr |
| Massachusetts | 29 | 1,871−4.2%/yr | −4.2%/yr | 2.00.8× | 38% | 2,190 in 2030+2.6%/yr |
| South Carolina | 22 | 1,644−1.1%/yr | −1.1%/yr | 2.41.0× | 69% | 1,760 in 2030+1.1%/yr |
| Michigan | 23 | 1,526−8.8%/yr | −8.8%/yr | 1.80.7× | 29% | 1,320 in 2030−2.3%/yr |
| Georgia | 19 | 1,497−3.1%/yr | −3.1%/yr | 1.80.7× | 88% | 1,580 in 2030+0.9%/yr |
| Indiana | 24 | 1,476−4.2%/yr | −4.2%/yr | 2.10.9× | 74% | 1,530 in 2030+0.6%/yr |
| Wisconsin | 18 | 1,472−1%/yr | −1%/yr | 2.61.1× | 29% | 1,730 in 2030+2.7%/yr |
| Oregon | 16 | 1,238−2.8%/yr | −2.8%/yr | 3.01.2× | 41% | 1,270 in 2030+0.4%/yr |
| Alabama | 18 | 1,215−6.6%/yr | −6.6%/yr | 2.81.1× | 45% | 1,170 in 2030−0.7%/yr |
| Minnesota | 21 | 1,192−4.8%/yr | −4.8%/yr | 2.71.1× | 73% | 1,540 in 2030+4.3%/yr |
| Kansas | 18 | 1,141−5.2%/yr | −5.2%/yr | 2.81.2× | 60% | 1,150 in 2030+0.2%/yr |
| Louisiana | 14 | 1,034−4.5%/yr | −4.5%/yr | 2.61.0× | 72% | 980 in 2030−1%/yr |
| Utah | 15 | 1,023−2.3%/yr | −2.3%/yr | 4.71.9× | 59% | 990 in 2030−0.6%/yr |
| Oklahoma | 14 | 1,019−4.8%/yr | −4.8%/yr | 2.10.9× | 77% | 1,020 in 2030+0.1%/yr |
| Mississippi | 11 | 1,000−1.3%/yr | −1.3%/yr | 2.71.1× | 72% | 1,010 in 2030+0.2%/yr |
| Kentucky | 16 | 944−6.8%/yr | −6.8%/yr | 2.10.8× | 85% | 910 in 2030−0.5%/yr |
| Iowa | 14 | 772+0.4%/yr | +0.4%/yr | 1.80.7× | 67% | 880 in 2030+2.2%/yr |
| Nebraska | 9 | 735−1.3%/yr | −1.3%/yr | 2.81.2× | 72% | 740 in 20300%/yr |
| Nevada | 10 | 723−1.9%/yr | −1.9%/yr | 2.51.0× | 8% | 850 in 2030+2.7%/yr |
| Arkansas | 10 | 687−6.8%/yr | −6.8%/yr | 1.80.7× | 0% | 580 in 2030−2.7%/yr |
| South Dakota | 7 | 578+4.1%/yr | +4.1%/yr | 4.51.8× | 100% | 1,010 in 2030+9.8%/yr |
| Idaho | 6 | 497+2.3%/yr | +2.3%/yr | 2.51.0× | 77% | 620 in 2030+3.7%/yr |
| New Mexico | 8 | 477−2%/yr | −2%/yr | 2.10.8× | 54% | 440 in 2030−1.5%/yr |
| Connecticut | 6 | 441−6.9%/yr | −6.9%/yr | 1.30.5× | 97% | 470 in 2030+1.1%/yr |
| Montana | 5 | 349−0.8%/yr | −0.8%/yr | 1.80.7× | 51% | 340 in 2030−0.3%/yr |
| Hawaii | 5 | 294−3.5%/yr | −3.5%/yr | 2.30.9× | 95% | 300 in 2030+0.3%/yr |
| Maine | 5 | 254−4%/yr | −4%/yr | 1.60.7× | 100% | 240 in 2030−1.2%/yr |
| West Virginia | 4 | 208−16%/yr | −16%/yr | 1.00.4× | 73% | 310 in 2030+6.8%/yr |
| New Hampshire | 3 | 201+0.6%/yr | +0.6%/yr | 0.90.4× | 89% | 290 in 2030+6.5%/yr |
| North Dakota | 2 | 184+6.1%/yr | +6.1%/yr | 1.90.8× | 73% | 130 in 2030−5.9%/yr |
| District of Columbia | 3 | 175−2.1%/yr | −2.1%/yr | 2.81.1× | 51% | 260 in 2030+6.9%/yr |
| Alaska | 1 | 154−1%/yr | −1%/yr | 1.30.5× | 100% | 130 in 2030−3%/yr |
| Rhode Island | 0 | 115−2.6%/yr | −2.6%/yr | 1.30.5× | 100% | 70 in 2030−8%/yr |
| Vermont | 2 | 101+27%/yr | +27%/yr | 0.90.4× | 0% | 180 in 2030+9.9%/yr |
Across the covered states the share outside the hospital has moved +12 pts since 2019, to 65%.
In 2025, 22 companies reported engagement with surgeons in the covered states worth $9.9M in consulting, speaking, meals and travel tied to these products, about $9,191 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.